VHAM
CPRX icon

Van Hulzen Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Van Hulzen Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-56
Closed -$1.17K – 461
2024
Q4 		$1.17K Buy
+56
New +$1.2K ﹤0.01% 1009

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Van Hulzen Asset Management's CPRX Position: Q1 2025 in Review

Van Hulzen Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2025, closing a stake of 56 shares — an estimated $1.17K sold.

Van Hulzen Asset Management first reported a position in CPRX in Q4 2024 and held it in 1 quarter. The position peaked at $1.17K in Q4 2024. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

  • Van Hulzen Asset Management reported no remaining Catalyst Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Van Hulzen Asset Management sold 56 Catalyst Pharmaceutical shares in Q1 2025, an estimated $1.17K.
  • Van Hulzen Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 1 quarter.
  • Van Hulzen Asset Management's Catalyst Pharmaceutical position peaked at $1.17K in Q4 2024.
  • 371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on Van Hulzen Asset Management's 13F filing for Q1 2025, filed 14 May 2025.